Stocks in play: Cardiol Therapeutics Inc.
Announced that it has surpassed 50% patient enrollment in MAVERIC, its Phase III randomized, double-blind, placebo-controlled, multi-center international trial evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis. Cardiol Therapeutics Inc. shares T.CRDL are trading unchanged at $1.35.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.